Study Design
Phase 3, randomized, double-blind, placebo-controlled trial of letrozole in postmenopausal women with primary breast cancer who had completed 4.5-6 years of tamoxifen therapy.
Women were randomly assigned to receive letrozole (2.5mg) or placebo daily for five years.